**Appendix no 1 – The bid form**

……………………………….. ……………………………….

………………………………. (place and date)

………………………………..

………………………………...

(name and address of the bidder)

**The bid for the proceeding: ABM/21/2024/ZF**

**Name of the order:**

**“Determination of in vitro ADME profile”**

Project: "Design and clinical development of the first-in-class small-molecule drug candidate in colorectal cancer therapy, based on the immune cells stimulation to enhanced anti-cancer activity through induced protein degradation."The project co-financed from the state budget from the Medical Research Agency under the Competition no. ABM/2022/6 entitled. "Development of targeted or personalized medicine based on therapy with nucleic acids or small-molecule compounds, KWAS". Contract No. 2022/ABM/06/00001 - 00.

1. **WE SUBMIT THE BID** for fulfilment of the subject of the order and we declare to fulfill it in accordance to the conditions defined in the invitation to submit a bid no ABM/21/2024/ZF.
2. **WE OFFER** the realization of the subject of order in net price indicated in the table :

|  |  |  |  |
| --- | --- | --- | --- |
| **Captor Therapeutics Inc. low-molecular chemical compounds profiling using in vitro ADME**  *Note: for a validity of the bid, the net price is required for all items in the table.* ***Only one price*** *should be given for a given test; if more than one price is given for a given test - the higher price will be taken into account for the bid evaluation.*  **The price should be expressed in United States Dollar (USD), Euro (EUR), Polish zloty (PLN)\* to two decimal places (to 1 cent rounded up).** | | | |
| **ADME in vitro studies (profiling) for a single compound\*\*[[1]](#footnote-1)** | | | **Net price for a single compound** **(USD/EUR/PLN)\*** |
| 1. | Kinetic Solubility | not less than 5 points of calibration curve, selected 1 pH | ……………………… |
| 2. | LogD | Analytical Method HPLC-UV confirmation by MS | ……………………… |
| 3. | Chemical Stability | not less than 1 buffer / pH, min 5 time points | ……………………… |
| 4. | Plasma stability - Species:  Human /CD-1 mouse/Rat SD | Min. 5-time points; | ……………………… |
| 5. | MDCK/ MDCK-MDR1 assay: Bidirectional | at least 1 conc, 1 time point | ……………………… |
| 6. | Caco-2 assay: Bidirectional | at least 1 conc, 1 time point | ……………………… |
| 7. | Plasma Protein Binding Species:  Human/ Mouse/Rat | at least 1 conc, LC-MS/MS | ……………………… |
| 8. | Microsomal stability; Species:  Mouse/ Human | at least 1 conc, Analysis with LC-MS/MS; | ……………………… |
| 9. | CYP Inhibition (1A2, 2B6, 2C9, 2D6, 3A4); CYP panel using 5 in 1 cocktail substrates | Incubation – human microsomes,  Min. 6 conc., IC50; LC-MS/MS | ……………………… |
| 10. | Hepatocyte Stability study; Species: Mouse/Human/Rat/ | Min. 1 conc. And 5 time points | ……………………… |
| 11. | hERG inhibition | IC50 | ……………………… |

All costs related to the realization of the order in accordance to the requirements specified in the invitation to submit a bid no ABM/21/2024/ZF are included in the price above.

1. **WE DECLARE** that:
   1. we have the permissions to perform a specific activity if the law imposes an obligation to hold it, to carry out the activity covered by the contract,
   2. During the contract execution we will have access to the group of specialists with the necessary knowledge, appropriate education and experience required for the service, including experts and consultants in the field of ADME studies. We confirm that we have completed at least two projects in the field of ADME studies for pharmaceutical industry partners within the last 3 years.
   3. his offer is public, except for the information contained on the pages ..................(fill in if applicable), which is a business secret within the meaning of the Anti-unfair Competition Act and as such may not be available to the public.

Being informed about responsibility for any false statement or concealment of truth, we hereby declare that the above data is true.

1. **WE CONSIDER OURSELVES** being bound with the bid for 60 days since the deadline of offers submission.
2. **ANY CORRESPONDENCE** on this proceeding should be addressed to:

Name and surname ………………………………….

Address …………………………………………………..

Phone numer …………………………………………

E-mail ……………………………………………………

1. **THIS BID** we submit on \_\_\_\_\_\_\_\_\_ numbered pages and attach the following statements and documents:

1)..............................................................................................

2)…………………………………………………………………………………………

3)…………………………………………………………………………………………

4)…………………………………………………………………………………………

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

(stamp and signature of the bidder)

1. \* - please choose one currency

   \*\* - The Bidder must have a full panel of tests in all variants listed by the Ordering Party. The Ordering party reserves the rights to choose the scope of research individually for each compound. The selection of studies depends on the results from the research work. [↑](#footnote-ref-1)